Ignite Creation Date:
2025-12-24 @ 11:13 PM
Ignite Modification Date:
2025-12-25 @ 8:48 PM
Study NCT ID:
NCT06862869
Status:
RECRUITING
Last Update Posted:
2025-12-12
First Post:
2025-02-20
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
Sponsor:
Hoffmann-La Roche
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-04-30
Start Date Type:
ACTUAL
Primary Completion Date:
2029-06-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2025-02-20
First Submit QC Date:
None
Study First Post Date:
2025-03-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-11
Last Update Post Date:
2025-12-12
Last Update Post Date Type:
ESTIMATED